The experimental use of surfagon, a synthetic analog of luliberin, in follicular ovarian cysts

The use of a synthetic peptide analog of LH-RH agonist--[D-Ala6, des Gly10, Pro9]-LH-RH ethylamide (surfagon) at microdoses and in short courses returned to normal the ovulatory cycle in the anovulatory condition in rats and caused luteinization of follicular cysts in rats and cows with further norm...

Full description

Saved in:
Bibliographic Details
Published inProblemy ėndokrinologii Vol. 35; no. 6; p. 54
Main Authors Krivosheev, O G, Chernykh, V Ia, Vinogradov, V A, Nabatchikova, N A, Siutkin, E A
Format Journal Article
LanguageRussian
Published Russia (Federation) 01.11.1989
Subjects
Animals
Anovulation - drug therapy
Anovulation - etiology
Cattle
Cattle Diseases - drug therapy
Dinoprost - therapeutic use
Drug Evaluation, Preclinical - veterinary
Female
Follicular Cyst - drug therapy
Follicular Cyst - etiology
Follicular Cyst - veterinary
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - therapeutic use
Hormones - therapeutic use
Luteinizing Hormone - blood
Ovarian Cysts - drug therapy
Ovarian Cysts - etiology
Ovarian Cysts - veterinary
Ovariectomy
Ovary - pathology
Rats
Rats, Inbred Strains
Online AccessGet more information

Cover

More Information
Summary:The use of a synthetic peptide analog of LH-RH agonist--[D-Ala6, des Gly10, Pro9]-LH-RH ethylamide (surfagon) at microdoses and in short courses returned to normal the ovulatory cycle in the anovulatory condition in rats and caused luteinization of follicular cysts in rats and cows with further normalization of ovarian function. It is assumed that surfagon will be effective for the treatment of anovulatory condition and ovarian follicular cysts in women.
ISSN:0375-9660